The use of anti-CTLA-4 antibodies in monotherapy and in combination with anti-PD-1/PD-L1 antibodies have been discredited, due to the lack of significant clinical response and high incidence of autoimmunity. The gene discussed is CTLA4; the disease is Autoimmunity.